Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.
Shanghai Fosun Pharmaceutical reported solid full-year 2025 results, with revenue edging up to RMB 41.5 billion and gross profit improving on a higher gross margin of 49.88%. Net profit attributable to shareholders rose to RMB 3.37 billion, lifting basic earnings per share to RMB 1.27, while total assets and equity also increased year on year.
Profitability strengthened as net profit margin climbed to 10.24%, supported by higher EBITDA of RMB 10.1 billion and increased contributions from associates, despite rising research and development spending and selling expenses. The results indicate improved operational efficiency and earnings quality, underscoring Fosun Pharma’s resilience in a competitive healthcare market and its continued investment in innovation-driven growth.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based pharmaceutical and healthcare group listed in Hong Kong. The company operates across drug research and development, manufacturing and distribution, as well as medical services, targeting both domestic and international healthcare markets.
Average Trading Volume: 2,964,154
Technical Sentiment Signal: Sell
Current Market Cap: HK$67.07B
See more insights into 2196 stock on TipRanks’ Stock Analysis page.